News Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-14 pm EDT			5-day change	1st Jan Change
178,600 ^KRW	-1.98%		-5.25%	-11.36%

Mar. 28	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.	CI
Mar. 26	Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.	Mar. 28	CI
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.	Mar. 25	CI
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.	Mar. 20	AQ
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US	Mar. 18	MT
Celltrion's Autoimmune Disease Treatment Hits US Markets	Mar. 18	MT
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed	Mar. 06	MT
Celltrion Announces 75 Billion Won Share Buyback Plan	Mar. 06	MT
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)	Mar. 05	AQ
Celltrion, Inc. announces an Equity Buyback for 425,895 shares.	Mar. 04	CI
Celltrion, Inc. authorizes a Buyback Plan.	Mar. 04	CI
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	Feb. 29	AQ
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings	Feb. 29	MT
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25%	Feb. 29	MT
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47	Feb. 29	AQ
Chugai, Genentech, And Hoffmann-La Roche Dismiss Appeals Of Actemra® Patent IPR Final Written Decisions	Feb. 29	AQ
Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease	Feb. 23	CI
Updates On Aflibercept BPCIA Litigation	Feb. 19	AQ
South Korean Shares Close Lower on Hotter-Than-Expected US Inflation Data	Feb. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Celltrion, Inc.

Equities

A068270

KR7068270008

Summary

Filters